胱胺酸尿症治療市場－全球產業規模、佔有率、趨勢、機會和預測，按類型、藥物、給藥途徑、配銷通路、地區和競爭格局分類，2020-2030年預測

2024年全球胱胺酸尿症治療市場價值為1.6億美元，預計2030年將以4.70%的複合年成長率成長至2.1077億美元。全球胱胺酸尿症治療市場涵蓋旨在預防和控制泌尿道胱胺酸結石復發的藥物和醫療干預措施，胱胺酸尿症是一種罕見的遺傳性疾病。

主要市場促進因素

新型治療藥物和治療方式的進步顯著推動了全球胱胺酸尿症治療市場的發展，帶來了更有效、耐受性更好的治療選擇。傳統的胱胺酸尿症治療方法往往副作用較大，導致患者依從性差，容易出現結石復發。

主要市場挑戰

胱胺酸尿症本身的罕見性對其治療市場的成長構成了重大挑戰。極少的患者群體直接限制了對新型治療方法進行廣泛研究和開發的商業可行性。

主要市場趨勢

一個顯著的趨勢是強調個人化醫療方法。這種方法是指根據患者的個別情況（通常基於特定的基因突變或疾病特徵）量身定做治療方案，以提高療效並最大限度地減少不良反應。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：客戶之聲

第5章：全球胱胺酸尿症治療市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依類型（胱胺酸尿症 1 型、胱胺酸尿症 2 型、胱胺酸尿症 3 型）
  • 依藥物分類（硫普羅寧、青黴胺、卡托普利、其他）
  • 依給藥途徑（口服、注射）
  • 按配銷通路（醫院藥房、零售藥房、網路藥房）
  • 按地區
  • 按公司（2024 年）
• 市場地圖

第6章：北美胱胺酸尿症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲胱胺酸尿症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區胱胺酸尿症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲胱胺酸尿症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲胱胺酸尿症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章：市場動態

• 促進要素
• 挑戰

第12章：市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章：全球胱胺酸尿症治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客的力量
• 替代產品的威脅

第15章：競爭格局

• Travere Therapeutics, Inc
• Dr. Reddy's Laboratories Ltd
• Advicenne SACA
• Teva Pharmaceutical Industries Ltd
• ANI Pharmaceuticals, Inc
• Viatris Inc
• Advanz Pharma Corp
• Camber Pharmaceuticals, Inc
• Bausch Health Companies Inc
• Synact Pharma AB

第16章：策略建議

第17章調查會社について,免責事項

The Global Cystinuria treatment Market, valued at USD 160.00 Million in 2024, is projected to experience a CAGR of 4.70% to reach USD 210.77 Million by 2030. The Global Cystinuria treatment market encompasses pharmaceutical and medical interventions designed to prevent and manage the recurrence of cystine calculi in the urinary tract, a manifestation of the rare genetic disorder, cystinuria.

Key Market Drivers

Advancements in Novel Therapeutic Agents and Treatment Modalities significantly propel the Global Cystinuria treatment market by introducing more effective and better tolerated options. Traditional treatments for this rare genetic disorder often presented considerable side effects, contributing to suboptimal patient adherence and persistent stone recurrence. The development of new compounds, drug classes, and innovative delivery methods promises improved outcomes and enhances patient quality of life. Progress in understanding disease pathophysiology facilitates targeted interventions.

Key Market Challenges

The inherent rarity of cystinuria presents a significant challenge to the growth of its treatment market. The extremely small patient population directly limits the commercial viability for extensive research and development into novel therapeutic approaches. Pharmaceutical companies encounter considerable financial risks when investing in treatments for conditions with such limited market potential, as the prospects of recouping substantial R&D costs are diminished. This specialized nature of therapies for rare disorders, coupled with the small patient pool, inevitably contributes to higher per-patient treatment expenses. Such elevated costs can severely restrict global accessibility and adoption, particularly within healthcare systems operating under constrained budgets, thereby hindering broader market penetration.

Key Market Trends

A prominent trend is the Emphasis on Personalized Medicine Approaches. This involves tailoring treatment regimens to individual patient profiles, often based on specific genetic mutations or disease characteristics, to enhance efficacy and minimize adverse effects. This approach marks a departure from conventional generalized treatments, promising more precise interventions for a rare genetic disorder like cystinuria.

Key Market Players

• Travere Therapeutics, Inc
• Dr. Reddy's Laboratories Ltd
• Advicenne SACA
• Teva Pharmaceutical Industries Ltd
• ANI Pharmaceuticals, Inc
• Viatris Inc
• Advanz Pharma Corp
• Camber Pharmaceuticals, Inc
• Bausch Health Companies Inc
• Synact Pharma AB

Report Scope:

In this report, the Global Cystinuria treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cystinuria treatment Market, By Type:

• Cystinuria Type 1
• Cystinuria Type 2
• Cystinuria Type 3

Cystinuria treatment Market, By Drugs:

• Tiopronin
• Penicillamine
• Captopril
• Others

Cystinuria treatment Market, By Route of Administration:

• Oral
• Injectables

Cystinuria treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Cystinuria treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Cystinuria treatment Market.

Available Customizations:

Global Cystinuria treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cystinuria treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Cystinuria Type 1, Cystinuria Type 2, Cystinuria Type 3)
  • 5.2.2. By Drugs (Tiopronin, Penicillamine, Captopril, Others)
  • 5.2.3. By Route of Administration (Oral, Injectables)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Cystinuria treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drugs
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cystinuria treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drugs
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Cystinuria treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drugs
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Cystinuria treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drugs
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel

7. Europe Cystinuria treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Drugs
  • 7.2.3. By Route of Administration
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cystinuria treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drugs
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Cystinuria treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drugs
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Cystinuria treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drugs
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Cystinuria treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Drugs
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Cystinuria treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Drugs
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Cystinuria treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drugs
  • 8.2.3. By Route of Administration
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cystinuria treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drugs
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Cystinuria treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drugs
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Cystinuria treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drugs
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Cystinuria treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Drugs
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Cystinuria treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Drugs
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Cystinuria treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drugs
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cystinuria treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drugs
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Cystinuria treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drugs
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Cystinuria treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drugs
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. South America Cystinuria treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Drugs
  • 10.2.3. By Route of Administration
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cystinuria treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Drugs
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Cystinuria treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Drugs
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Cystinuria treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Drugs
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cystinuria treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Travere Therapeutics, Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Dr. Reddy's Laboratories Ltd
• 15.3. Advicenne SACA
• 15.4. Teva Pharmaceutical Industries Ltd
• 15.5. ANI Pharmaceuticals, Inc
• 15.6. Viatris Inc
• 15.7. Advanz Pharma Corp
• 15.8. Camber Pharmaceuticals, Inc
• 15.9. Bausch Health Companies Inc
• 15.10. Synact Pharma AB

16. Strategic Recommendations

17. About Us & Disclaimer